v3.26.3
Segment Information - Schedule of Research and Development Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Total $ 68,374 $ 63,352 $ 145,774 $ 151,356
Affordable Medicines | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits 12,343 13,905 37,382 42,139
Materials and supplies 6,944 6,230 24,555 22,865
Product development and studies 127 673 963 1,360
In-licensing and upfront milestones 0 22,500 4,000 29,100
Facilities costs 1,654 1,755 4,623 5,182
Regulatory fees 704 2,317 4,432 4,834
Kashiv R&D expenses 19,421 0 19,421 0
Other 22,225 7,744 34,351 22,523
Total 63,418 55,124 129,727 128,003
Affordable Medicines | Orion Corporation        
Segment Reporting [Line Items]        
Product development and studies (1,000) 1,300 (2,700) 3,800
Specialty | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits 1,658 1,089 4,303 3,908
Materials and supplies 842 1,358 1,924 2,011
Product development and studies 1,715 2,823 7,108 7,513
In-licensing and upfront milestones 0 0 0 3,000
Facilities costs 45 409 110 1,894
Regulatory fees 0 0 0 0
Kashiv R&D expenses 0 0 0 0
Other 696 2,549 2,602 5,027
Total 4,956 8,228 16,047 23,353
Specialty | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits $ 13,315 $ 10,972 $ 38,188 $ 32,635